Oral Alzheimer's Candidate AR1001 Advances on Patents
Early-stage Alzheimer's patients may eventually have an oral option, but Phase 3 results are not yet available.
Updated on Nov. 3, 2026 in Alzheimer’s
AriBio has registered a Japanese patent for AR1001 (mirodenafil), an oral candidate treatment for Alzheimer's disease, and the European Patent Office has issued a notification of intended patent registration for the same compound. The patent covers the use of PDE-5 inhibitors for Alzheimer's and their role in inhibiting amyloid beta aggregation into oligomers and fibrils.
Why it matters
Patent protection signals that AR1001 is advancing toward possible commercialization for early-stage Alzheimer's patients, a population with few oral treatment options in development. The filings were jointly submitted with SK Chemicals and reflect ongoing efforts to build intellectual property around the candidate as later-stage results approach.
The patent filings rest on AR1001's global Phase 3 POLARIS AD trial in early-stage Alzheimer's patients, though this announcement reports no trial outcome data. Topline results are scheduled for presentation at CTAD 2026 in Boston on November 16, 2026, and remain unpublished at the time of the filing.
The players
AriBio
AriBio is a South Korean biopharmaceutical company developing AR1001, an oral treatment candidate for Alzheimer's disease.
SK Chemicals
SK Chemicals is a South Korean chemical and life sciences company that jointly filed the AR1001 patent with AriBio.
The details
AR1001 is an oral candidate that targets several pathological processes of Alzheimer's disease through inhibition of PDE-5, an enzyme that breaks down cGMP, a signaling molecule that dilates blood vessels. The patent claims cover this PDE-5 inhibition approach as well as the reduction of amyloid beta aggregation into oligomers and fibrils. AriBio is also pursuing follow-up patent applications and product lifecycle management strategies around the compound.
Timeline
AriBio acquired a U.S. patent for AR1001 in 2025.
AriBio announced the Japanese patent registration and European notification on November 3, 2026.
Topline Phase 3 POLARIS AD results are scheduled for presentation at CTAD 2026 in Boston on November 16, 2026.
Health Landscape
Most Alzheimer's drugs that have reached the market target amyloid or tau, and oral options with a different mechanism remain limited in late-stage development. AR1001 is positioned as a PDE-5 inhibitor candidate pursued as a multi-target approach to the disease.
For people living with or caring for someone with early-stage Alzheimer's, an oral treatment candidate reaching Phase 3 results is worth following as it develops. Anyone interested in this option should discuss current treatment choices and trial eligibility with their physician or neurologist.
The takeaway
AR1001 is an oral Alzheimer's candidate whose Phase 3 results are due at CTAD 2026 on November 16. Anyone tracking new treatment options can ask their doctor whether clinical trial participation or upcoming results are relevant to their situation.
What happens next
Topline Phase 3 POLARIS AD results for AR1001 will be presented at CTAD 2026 in Boston on November 16, 2026.
Further reading
For broader context on treatment development, see the Alzheimer’s section.
